Exact Mass: 1068.4561068

Exact Mass Matches: 1068.4561068

Found 48 metabolites which its exact mass value is equals to given mass value 1068.4561068, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Desmopressin

(2S)-2-({[(2S)-1-[(4R,7S,10S,13S,16S)-13-benzyl-6,9,12,15,18-pentahydroxy-10-[2-(C-hydroxycarbonimidoyl)ethyl]-7-[(C-hydroxycarbonimidoyl)methyl]-16-[(4-hydroxyphenyl)methyl]-1,2-dithia-5,8,11,14,17-pentaazacycloicosa-5,8,11,14,17-pentaene-4-carbonyl]pyrrolidin-2-yl](hydroxy)methylidene}amino)-5-carbamimidamido-N-[(C-hydroxycarbonimidoyl)methyl]pentanimidate

C46H64N14O12S2 (1068.4269344)


Desmopressin is a chemical that is similar to Antidiuretic Hormone (ADH) which is found naturally in the body. It increases urine concentration and decreases urine production. Desmopressin is used to prevent and control excessive thirst, urination, and dehydration caused by injury, surgery, and certain medical conditions, allowing you to sleep through the night without awakening to urinate. It is also used to treat specific types of diabetes insipidus and conditions after head injury or pituitary surgery. H - Systemic hormonal preparations, excl. sex hormones and insulins > H01 - Pituitary and hypothalamic hormones and analogues > H01B - Posterior pituitary lobe hormones > H01BA - Vasopressin and analogues C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C80212 - Antidiuretic Hormone Analogue D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D014667 - Vasopressins D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D006401 - Hematologic Agents > D003029 - Coagulants > D006490 - Hemostatics D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D050034 - Antidiuretic Agents

   

PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

{[(1R,3S)-3-({[(2R)-2-{[(5Z,7R,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-3-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(4Z,7Z,10Z,13Z,16Z))

{[(1R,3S)-3-({[(2R)-3-{[(5Z,7S,8E,10Z,13Z,15E,17R,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-2-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(4Z,7Z,10Z,13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of Resolvin D5 at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

{[(1R,3S)-3-({[(2R)-2-{[(4Z,7Z,10R,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-3-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-1 position and one chain of Protectin DX at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(4Z,7Z,10Z,13Z,16Z))

{[(1R,3S)-3-({[(2R)-3-{[(4Z,7Z,10S,11E,13Z,15E,17R,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-2-[(4Z,7Z,10Z,13Z,16Z)-docosa-4,7,10,13,16-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(4Z,7Z,10Z,13Z,16Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of Protectin DX at the C-1 position and one chain of 4Z,7Z,10Z,13Z,16Z-docosapentaenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

{[(1R,3S)-3-({[(2R)-2-{[(5Z,7R,8E,10Z,13Z,15E,17S,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)), in particular, consists of one chain of 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-1 position and one chain of Resolvin D5 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(7Z,10Z,13Z,16Z,19Z))

{[(1R,3S)-3-({[(2R)-3-{[(5Z,7S,8E,10Z,13Z,15E,17R,19Z)-7,17-dihydroxydocosa-5,8,10,13,15,19-hexaenoyl]oxy}-2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of Resolvin D5 at the C-1 position and one chain of 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

{[(1R,3S)-3-({[(2R)-2-{[(4Z,7Z,10R,11E,13Z,15E,17S,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)), in particular, consists of one chain of 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-1 position and one chain of Protectin DX at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(7Z,10Z,13Z,16Z,19Z))

{[(1R,3S)-3-({[(2R)-3-{[(4Z,7Z,10S,11E,13Z,15E,17R,19Z)-10,17-dihydroxydocosa-4,7,11,13,15,19-hexaenoyl]oxy}-2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyloxy]propoxy](hydroxy)phosphoryl}oxy)-2,4,5,6-tetrahydroxycyclohexyl]oxy}phosphonic acid

C53H82O18P2 (1068.4976132)


PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(7Z,10Z,13Z,16Z,19Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of Protectin DX at the C-1 position and one chain of 7Z,10Z,13Z,16Z,19Z-docosapentaenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.

   
   
   
   

landomycin U

landomycin U

C55H72O21 (1068.4565862)


A natural product found in Streptomyces cyanogenus.

   

beta-D-glucopyranosyl-(1?3)-beta-D-glucopyranosyl-(1?3)-[6-O-(E)-p-methoxycinnamoyl]-beta-D-glucopyranosyl-(1?2)-[4-O-((E)-2-(4-acetamidobutylcarbamoyl)vinyl)-phenyl]-alpha-L-rhamnopyranoside|clerodendiod A

beta-D-glucopyranosyl-(1?3)-beta-D-glucopyranosyl-(1?3)-[6-O-(E)-p-methoxycinnamoyl]-beta-D-glucopyranosyl-(1?2)-[4-O-((E)-2-(4-acetamidobutylcarbamoyl)vinyl)-phenyl]-alpha-L-rhamnopyranoside|clerodendiod A

C49H68N2O24 (1068.4161808000001)


   

(2S,4R)-1-[(3R,6S,9R,14R,17S,20S)-9-amino-17-(2-amino-2-oxoethyl)-3-benzyl-6-[(4-hydroxyphenyl)methyl]-2,5,8,16,19-pentaoxo-11,12-dithia-1,4,7,15,18-pentazabicyclo[18.3.0]tricosane-14-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneam

(2S,4R)-1-[(3R,6S,9R,14R,17S,20S)-9-amino-17-(2-amino-2-oxoethyl)-3-benzyl-6-[(4-hydroxyphenyl)methyl]-2,5,8,16,19-pentaoxo-11,12-dithia-1,4,7,15,18-pentazabicyclo[18.3.0]tricosane-14-carbonyl]-N-[(2S)-1-[(2-amino-2-oxoethyl)amino]-5-(diaminomethylideneam

C46H64N14O12S2 (1068.4269344)


   

ALPHA-FUC-[1->2]-BETA-GAL-[1->3]-(ALPHA-FUC-[1->4])-BETA-GLCNAC-[1->3]-BETA-GAL-[1->4]-(ALPHA-FUC-[1->3])-BETA-GLCNAC-[1->3]-BETA-GAL-[1->4]-GLC

ALPHA-FUC-[1->2]-BETA-GAL-[1->3]-(ALPHA-FUC-[1->4])-BETA-GLCNAC-[1->3]-BETA-GAL-[1->4]-(ALPHA-FUC-[1->3])-BETA-GLCNAC-[1->3]-BETA-GAL-[1->4]-GLC

C42H72N2O29 (1068.4220542)


   
   

PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C53H82O18P2 (1068.4976132)


   

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(4Z,7Z,10Z,13Z,16Z))

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(4Z,7Z,10Z,13Z,16Z))

C53H82O18P2 (1068.4976132)


   

PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

PIP(22:5(4Z,7Z,10Z,13Z,16Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C53H82O18P2 (1068.4976132)


   

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(4Z,7Z,10Z,13Z,16Z))

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(4Z,7Z,10Z,13Z,16Z))

C53H82O18P2 (1068.4976132)


   

PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S))

C53H82O18P2 (1068.4976132)


   

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(7Z,10Z,13Z,16Z,19Z))

PIP(22:6(5Z,8E,10Z,13Z,15E,19Z)-2OH(7S, 17S)/22:5(7Z,10Z,13Z,16Z,19Z))

C53H82O18P2 (1068.4976132)


   

PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

PIP(22:5(7Z,10Z,13Z,16Z,19Z)/22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17))

C53H82O18P2 (1068.4976132)


   

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(7Z,10Z,13Z,16Z,19Z))

PIP(22:6(4Z,7Z,11E,13Z,15E,19Z)-2OH(10S,17)/22:5(7Z,10Z,13Z,16Z,19Z))

C53H82O18P2 (1068.4976132)


   
   

DESMOPRESSIN

(Deamino-Cys1,D-Arg8)-Vasopressin acetate salt

C46H64N14O12S2 (1068.4269344)


H - Systemic hormonal preparations, excl. sex hormones and insulins > H01 - Pituitary and hypothalamic hormones and analogues > H01B - Posterior pituitary lobe hormones > H01BA - Vasopressin and analogues C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C80212 - Antidiuretic Hormone Analogue D002317 - Cardiovascular Agents > D014662 - Vasoconstrictor Agents > D014667 - Vasopressins D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones D006401 - Hematologic Agents > D003029 - Coagulants > D006490 - Hemostatics D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D045283 - Natriuretic Agents > D050034 - Antidiuretic Agents

   
   
   
   
   

(1s,2s,4s,5r,8r,9r,10s,13s,14r,17r,18r,20s)-10-{[(2r,3r,4s,5s,6r)-4-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-(sulfooxy)oxan-2-yl]oxy}-5-hydroxy-6-methyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-hydroxy-9,20-bis(hydroxymethyl)-4,5,9,13-tetramethyl-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-ene-20-carboxylic acid

(1s,2s,4s,5r,8r,9r,10s,13s,14r,17r,18r,20s)-10-{[(2r,3r,4s,5s,6r)-4-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-(sulfooxy)oxan-2-yl]oxy}-5-hydroxy-6-methyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-hydroxy-9,20-bis(hydroxymethyl)-4,5,9,13-tetramethyl-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-ene-20-carboxylic acid

C48H76O24S (1068.4447016)


   

2-[({4,5-dihydroxy-3-[(1-hydroxy-2-{[(2e,4e)-1-hydroxy-4,6,14-trimethylhexadeca-2,4-dien-1-ylidene]amino}ethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy(hydroxy)phosphoryl)oxy]-4-[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanoic acid

2-[({4,5-dihydroxy-3-[(1-hydroxy-2-{[(2e,4e)-1-hydroxy-4,6,14-trimethylhexadeca-2,4-dien-1-ylidene]amino}ethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy(hydroxy)phosphoryl)oxy]-4-[(2r,3s,4r,5r)-3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanoic acid

C45H73N4O23P (1068.4402998)


   

n-{5-[(3-bromo-4-methoxyphenyl)methyl]-15-(3-carbamimidamidopropyl)-6,13,16,21-tetrahydroxy-8-isopropyl-4,11-dimethyl-3,9,22-trioxo-2-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl}-2-[(1-hydroxybutylidene)amino]-4-methanesulfinylbutanimidic acid

n-{5-[(3-bromo-4-methoxyphenyl)methyl]-15-(3-carbamimidamidopropyl)-6,13,16,21-tetrahydroxy-8-isopropyl-4,11-dimethyl-3,9,22-trioxo-2-(sec-butyl)-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl}-2-[(1-hydroxybutylidene)amino]-4-methanesulfinylbutanimidic acid

C46H73BrN10O12S (1068.4313238)


   

(1s,2s,4s,5r,8r,9r,10s,13s,14r,17s,18r,20s)-10-{[(2r,3r,4s,5s,6r)-4-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-(sulfooxy)oxan-2-yl]oxy}-5-hydroxy-6-methyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-hydroxy-9,20-bis(hydroxymethyl)-4,5,9,13-tetramethyl-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-ene-20-carboxylic acid

(1s,2s,4s,5r,8r,9r,10s,13s,14r,17s,18r,20s)-10-{[(2r,3r,4s,5s,6r)-4-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-(sulfooxy)oxan-2-yl]oxy}-5-hydroxy-6-methyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-hydroxy-9,20-bis(hydroxymethyl)-4,5,9,13-tetramethyl-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-ene-20-carboxylic acid

C48H76O24S (1068.4447016)


   

n-(6-{[(7e,11e)-17-{[5-(acetyloxy)-4-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl]oxy}-3-formyl-5,25-dihydroxy-8,12,18,20,22-pentamethyl-23,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-3,7,11,14,24-pentaen-9-yl]oxy}-2,4-dimethyl-4-nitrooxan-3-yl)methoxycarboximidic acid

n-(6-{[(7e,11e)-17-{[5-(acetyloxy)-4-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl]oxy}-3-formyl-5,25-dihydroxy-8,12,18,20,22-pentamethyl-23,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-3,7,11,14,24-pentaen-9-yl]oxy}-2,4-dimethyl-4-nitrooxan-3-yl)methoxycarboximidic acid

C55H76N2O19 (1068.5042026)


   

1,11-dihydroxy-8-{[4-hydroxy-5-({5-hydroxy-4-[(5-{[4-hydroxy-5-({5-hydroxy-4-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-3-methyltetraphene-7,12-dione

1,11-dihydroxy-8-{[4-hydroxy-5-({5-hydroxy-4-[(5-{[4-hydroxy-5-({5-hydroxy-4-[(5-hydroxy-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl)oxy]-6-methyloxan-2-yl}oxy)-6-methyloxan-2-yl]oxy}-3-methyltetraphene-7,12-dione

C55H72O21 (1068.4565862)


   

(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-[(3-bromo-4-methoxyphenyl)methyl]-2-[(2s)-butan-2-yl]-15-(3-carbamimidamidopropyl)-6,13,16,21-tetrahydroxy-8-isopropyl-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-[(1-hydroxybutylidene)amino]-4-[(r)-methanesulfinyl]butanimidic acid

(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-[(3-bromo-4-methoxyphenyl)methyl]-2-[(2s)-butan-2-yl]-15-(3-carbamimidamidopropyl)-6,13,16,21-tetrahydroxy-8-isopropyl-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-[(1-hydroxybutylidene)amino]-4-[(r)-methanesulfinyl]butanimidic acid

C46H73BrN10O12S (1068.4313238)


   

6-{[(4z,6z,10z,14z,16z)-2-acetyl-17-[({5-[2-(3,5-dichloro-2-ethyl-4,6-dihydroxyphenyl)-1-hydroxy-2-oxoethyl]-4-hydroxy-3-methoxy-6-methyloxan-2-yl}oxy)methyl]-9-ethyl-12-hydroxy-5,7,11-trimethyl-18-oxo-1-oxacyclooctadeca-4,6,10,14,16-pentaen-8-yl]oxy}-4,5-dihydroxy-2,2-dimethyloxan-3-yl 2-methylpropanoate

6-{[(4z,6z,10z,14z,16z)-2-acetyl-17-[({5-[2-(3,5-dichloro-2-ethyl-4,6-dihydroxyphenyl)-1-hydroxy-2-oxoethyl]-4-hydroxy-3-methoxy-6-methyloxan-2-yl}oxy)methyl]-9-ethyl-12-hydroxy-5,7,11-trimethyl-18-oxo-1-oxacyclooctadeca-4,6,10,14,16-pentaen-8-yl]oxy}-4,5-dihydroxy-2,2-dimethyloxan-3-yl 2-methylpropanoate

C53H74Cl2O18 (1068.4251964)


   

2-[({4,5-dihydroxy-3-[(1-hydroxy-2-{[(2e,4e)-1-hydroxy-4,6,14-trimethylhexadeca-2,4-dien-1-ylidene]amino}ethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy(hydroxy)phosphoryl)oxy]-4-[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanoic acid

2-[({4,5-dihydroxy-3-[(1-hydroxy-2-{[(2e,4e)-1-hydroxy-4,6,14-trimethylhexadeca-2,4-dien-1-ylidene]amino}ethylidene)amino]-6-(hydroxymethyl)oxan-2-yl}oxy(hydroxy)phosphoryl)oxy]-4-[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanoic acid

C45H73N4O23P (1068.4402998)


   

(1s,2s,4s,5r,8r,9r,10s,13s,14r,18r,20s)-10-{[(2r,3r,4s,5s,6r)-4-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-(sulfooxy)oxan-2-yl]oxy}-5-hydroxy-6-methyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-hydroxy-9,20-bis(hydroxymethyl)-4,5,9,13-tetramethyl-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-ene-20-carboxylic acid

(1s,2s,4s,5r,8r,9r,10s,13s,14r,18r,20s)-10-{[(2r,3r,4s,5s,6r)-4-{[(2s,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-(sulfooxy)oxan-2-yl]oxy}-5-hydroxy-6-methyl-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-2-hydroxy-9,20-bis(hydroxymethyl)-4,5,9,13-tetramethyl-24-oxahexacyclo[15.5.2.0¹,¹⁸.0⁴,¹⁷.0⁵,¹⁴.0⁸,¹³]tetracos-15-ene-20-carboxylic acid

C48H76O24S (1068.4447016)


   

2-({[4,5-dihydroxy-3-({1-hydroxy-2-[(1-hydroxy-4,6,14-trimethylhexadeca-2,4-dien-1-ylidene)amino]ethylidene}amino)-6-(hydroxymethyl)oxan-2-yl]oxy(hydroxy)phosphoryl}oxy)-4-[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanoic acid

2-({[4,5-dihydroxy-3-({1-hydroxy-2-[(1-hydroxy-4,6,14-trimethylhexadeca-2,4-dien-1-ylidene)amino]ethylidene}amino)-6-(hydroxymethyl)oxan-2-yl]oxy(hydroxy)phosphoryl}oxy)-4-[3,4-dihydroxy-5-(4-hydroxy-2-oxopyrimidin-1-yl)oxolan-2-yl]-3-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}butanoic acid

C45H73N4O23P (1068.4402998)


   

[(1s,3as,3bs,5s,5as,7s,9as,11as)-5-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-4-{[(2s,3r,4s,5r)-4-hydroxy-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-1-[(2s)-2-hydroxy-6-methyl-4-oxoheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid

[(1s,3as,3bs,5s,5as,7s,9as,11as)-5-{[(2r,3r,4s,5r,6r)-3,5-dihydroxy-4-{[(2s,3r,4s,5r)-4-hydroxy-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-5-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-1-[(2s)-2-hydroxy-6-methyl-4-oxoheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,5h,5ah,6h,7h,8h,9h,11h-cyclopenta[a]phenanthren-7-yl]oxidanesulfonic acid

C49H80O23S (1068.4810850000001)


   

6-({2-acetyl-17-[({5-[2-(3,5-dichloro-2-ethyl-4,6-dihydroxyphenyl)-1-hydroxy-2-oxoethyl]-4-hydroxy-3-methoxy-6-methyloxan-2-yl}oxy)methyl]-9-ethyl-12-hydroxy-5,7,11-trimethyl-18-oxo-1-oxacyclooctadeca-4,6,10,14,16-pentaen-8-yl}oxy)-4,5-dihydroxy-2,2-dimethyloxan-3-yl 2-methylpropanoate

6-({2-acetyl-17-[({5-[2-(3,5-dichloro-2-ethyl-4,6-dihydroxyphenyl)-1-hydroxy-2-oxoethyl]-4-hydroxy-3-methoxy-6-methyloxan-2-yl}oxy)methyl]-9-ethyl-12-hydroxy-5,7,11-trimethyl-18-oxo-1-oxacyclooctadeca-4,6,10,14,16-pentaen-8-yl}oxy)-4,5-dihydroxy-2,2-dimethyloxan-3-yl 2-methylpropanoate

C53H74Cl2O18 (1068.4251964)


   

n-[(2r,3s,4s,6r)-6-{[(1s,5s,6s,9r,11z,13s,16s,17s,18r,20s,21s,22r)-17-{[(2r,4s,5r,6r)-5-(acetyloxy)-4-{[(2r,5s,6r)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-3-formyl-5,23-dihydroxy-8,12,18,20,22-pentamethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-3,7,11,14,23-pentaen-9-yl]oxy}-2,4-dimethyl-4-nitrooxan-3-yl]methoxycarboximidic acid

n-[(2r,3s,4s,6r)-6-{[(1s,5s,6s,9r,11z,13s,16s,17s,18r,20s,21s,22r)-17-{[(2r,4s,5r,6r)-5-(acetyloxy)-4-{[(2r,5s,6r)-5-hydroxy-6-methyloxan-2-yl]oxy}-6-methyloxan-2-yl]oxy}-3-formyl-5,23-dihydroxy-8,12,18,20,22-pentamethyl-25,27-dioxo-26-oxapentacyclo[22.2.1.0¹,⁶.0¹³,²².0¹⁶,²¹]heptacosa-3,7,11,14,23-pentaen-9-yl]oxy}-2,4-dimethyl-4-nitrooxan-3-yl]methoxycarboximidic acid

C55H76N2O19 (1068.5042026)


   

(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-[(3-bromo-4-methoxyphenyl)methyl]-2-[(2s)-butan-2-yl]-15-(3-carbamimidamidopropyl)-6,13,16,21-tetrahydroxy-8-isopropyl-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-[(1-hydroxybutylidene)amino]-4-methanesulfinylbutanimidic acid

(2s)-n-[(2s,5s,8s,11r,12s,15s,18s,21r)-5-[(3-bromo-4-methoxyphenyl)methyl]-2-[(2s)-butan-2-yl]-15-(3-carbamimidamidopropyl)-6,13,16,21-tetrahydroxy-8-isopropyl-4,11-dimethyl-3,9,22-trioxo-10-oxa-1,4,7,14,17-pentaazabicyclo[16.3.1]docosa-6,13,16-trien-12-yl]-2-[(1-hydroxybutylidene)amino]-4-methanesulfinylbutanimidic acid

C46H73BrN10O12S (1068.4313238)